Recent Updates
Recently added Catalysts

Evolocumab Drug Substance A

Phase 1

Healthy Participants | Small molecule | Other |Amgen Inc.|Last Updated: Apr 22, 2026

Success Probability
Approval Probability 71%
TA Base Rate26%
Adjusted LOA41%
ML RiskLOW_RISK
Premium
Market & Valuation
rNPV $3.2B
Market Size $9.4B
Revenue Basis $1.6B
Competitors 6
Premium
Trial Design
RandomizedCONTROLLED
Total Trials2
Total Enrollment800
FDA Designations
No designations recorded
Clinical Trials (2)
NCT IDTitlePhaseStatusEnrollmentVelocityDesignStartCompletionLast UpdatedSitesCountries
NCT07545226Comparing the Extent to Which Two Evolocumab Drug Products Are Made Available in the Body After a Single Subcutaneous Dose.PHASE1 NOT YET_RECRUITING 400Apr 20, 2026Sep 8, 2026Apr 22, 2026 -
NCT07422285Comparing the Extent to Which Two Evolocumab Drug Products Are Made Available in the Body After a Single Subcutaneous DosePHASE1 RECRUITING 400Jan 16, 2026Jun 30, 2026Apr 16, 20265 United States
Unlock Drug Trial Details
Study Endpoints
Primary Endpoints
Area Under the Concentration-time Curve (AUC) from Time 0 Extrapolated to Infinity (AUCinf) of Evolocumab
Day 1 to Day 64
AUC from Time 0 to Time of Last Quantifiable Concentration (AUClast) of Evolocumab
Day 1 to Day 64
Maximum Observed Concentration (Cmax) of Evolocumab
Day 1 to Day 64
Area Under the Concentration-time Curve from Time 0 to Time of Last Quantifiable Concentration (AUClast) of Evolocumab
Day 1 to Day 64
Secondary Endpoints
Number of Participants with Treatment-emergent Adverse Events (TEAEs)
Day 1 to Day 64
Number of Participants with Serious Adverse Events (SAEs)
Up to Day 64
Number of Participants with Anti-evolocumab Antibody Formation
Day 1 and Day 64
Unlock Study Endpoints
Study Design & Arms
AllocationRANDOMIZED
MaskingNONE
ModelPARALLEL
PurposeBASIC_SCIENCE
Treatment Arms
ArmTypeDescription
Evolocumab Drug Substance A (Test)EXPERIMENTALParticipants will receive a single subcutaneous (SC) dose of evolocumab drug substance A.
Evolocumab Drug Substance B (Reference)EXPERIMENTALParticipants will receive a single SC dose of evolocumab drug substance B.
Evolocumab Drug Substance AEXPERIMENTALParticipants will receive a single subcutaneous (SC) dose of evolocumab drug substance A.
Evolocumab Drug Substance BEXPERIMENTALParticipants will receive a single SC dose of evolocumab drug substance B.
Interventions
NameTypeDescription
Evolocumab Drug Substance A (Test)DRUGEvolocumab drug substance A will be administered SC.
Evolocumab Drug Substance B (Reference)DRUGEvolocumab drug substance B will be administered SC.
Evolocumab Drug Substance ADRUGEvolocumab drug substance A will be administered SC.
Evolocumab Drug Substance BDRUGEvolocumab drug substance B will be administered SC.
Unlock Study Design Details
Eligibility Criteria
Age Range18 Years — 60 Years
SexALL
Healthy VolunteersYes

Inclusion Criteria: 1. Male or female, of any race, between 18 and 60 years of age, inclusive. a. Females must not be pregnant or lactating. 2. Body mass index (BMI) between 18.0 and 32.0 kg/m\^2 inclusive. 3. LDL-C level ≥ 70 mg/dL (1.8 mmol/L) and ≤ 190 mg/dL (4.9 mmol/L) at screening. Exclu...

Countries:United States
Unlock Eligibility Criteria
Recent Changes (Last 90 Days)
LOWMay 26, 2026NCT07422285primaryCompletionDate: changed
LOWMay 26, 2026NCT07545226primaryCompletionDate: changed
LOWMay 24, 2026NCT07422285studyFirstPostDate: changed
LOWMay 24, 2026NCT07545226studyFirstPostDate: changed
LOWMay 21, 2026NCT07545226NEW_TRIAL: changed
LOWMay 21, 2026NCT07545226NEW_TRIAL: changed